Comprehensive Analysis of GABA


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 01 2020
Historique:
received: 30 11 2019
revised: 03 01 2020
accepted: 10 01 2020
entrez: 18 1 2020
pubmed: 18 1 2020
medline: 7 10 2020
Statut: epublish

Résumé

Rett syndrome, a serious neurodevelopmental disorder, has been associated with an altered expression of different synaptic-related proteins and aberrant glutamatergic and γ-aminobutyric acid (GABA)ergic neurotransmission. Despite its severity, it lacks a therapeutic option. Through this work we aimed to define the relationship between MeCP2 and GABAA.-A1 receptor expression, emphasizing the time dependence of such relationship. For this, we analyzed the expression of the ionotropic receptor subunit in different MeCP2 gene-dosage and developmental conditions, in cells lines, and in primary cultured neurons, as well as in different developmental stages of a Rett mouse model. Further, RNAseq and systems biology analysis was performed from post-mortem brain biopsies of Rett patients. We observed that the modulation of the MeCP2 expression in cellular models (both Neuro2a (N2A) cells and primary neuronal cultures) revealed a MeCP2 positive effect on the GABAA.-A1 receptor subunit expression, which did not occur in other proteins such as KCC2 (Potassium-chloride channel, member 5). In the Mecp2+/- mouse brain, both the KCC2 and GABA subunits expression were developmentally regulated, with a decreased expression during the pre-symptomatic stage, while the expression was variable in the adult symptomatic mice. Finally, the expression of the gamma-aminobutyric acid (GABA) receptor-related synaptic proteins from the postmortem brain biopsies of two Rett patients was evaluated, specifically revealing the GABA A1R subunit overexpression. The identification of the molecular changes along with the Rett syndrome prodromic stages strongly endorses the importance of time frame when addressing this disease, supporting the need for a neurotransmission-targeted early therapeutic intervention.

Identifiants

pubmed: 31947619
pii: ijms21020518
doi: 10.3390/ijms21020518
pmc: PMC7014188
pii:
doi:

Substances chimiques

GABRA1 protein, human 0
Receptors, GABA-A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI15/01159, PI16/00851, PI15/01082
Pays : International
Organisme : Mi Princesa Rett
ID : -
Pays : International

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Front Cell Neurosci. 2019 Feb 20;13:48
pubmed: 30842727
Mediators Inflamm. 2017;2017:9467819
pubmed: 28592917
Behav Pharmacol. 2008 Sep;19(5-6):501-17
pubmed: 18690105
Biochem Soc Trans. 2010 Apr;38(2):498-506
pubmed: 20298210
Nat Genet. 2001 Mar;27(3):322-6
pubmed: 11242117
J Neurophysiol. 2010 May;103(5):2470-81
pubmed: 20200124
J Neurobiol. 2003 Apr;55(1):86-96
pubmed: 12605461
Sci Transl Med. 2019 Jul 31;11(503):
pubmed: 31366578
J Biol Chem. 2004 Oct 1;279(40):41422-35
pubmed: 15258161
Orphanet J Rare Dis. 2016 Nov 25;11(1):158
pubmed: 27884167
J Neurosci. 2010 Apr 14;30(15):5346-56
pubmed: 20392956
Neuromolecular Med. 2014 Jun;16(2):231-64
pubmed: 24615633
Elife. 2016 Jun 21;5:
pubmed: 27328325
Biol Psychiatry. 2018 Jan 15;83(2):160-172
pubmed: 28734458
Front Mol Neurosci. 2008 May 30;1:7
pubmed: 18946540
Trends Neurosci. 1996 Apr;19(4):139-43
pubmed: 8658597
Sci Rep. 2019 Jun 25;9(1):9276
pubmed: 31239460
Molecules. 2018 Jun 22;23(7):
pubmed: 29932138
Genet Test. 2002 Spring;6(1):1-6
pubmed: 12180070
Neuropsychopharmacology. 2013 Jan;38(1):212-9
pubmed: 22781840
Mediators Inflamm. 2014;2014:480980
pubmed: 24511209
Neurobiol Dis. 2018 Jan;109(Pt A):25-32
pubmed: 28927958
Curr Psychiatry Rep. 2010 Apr;12(2):127-34
pubmed: 20425298
Front Mol Neurosci. 2019 Jul 23;12:173
pubmed: 31396048
Hippocampus. 2015 Feb;25(2):159-68
pubmed: 25209930
Nat Neurosci. 2018 Dec;21(12):1670-1679
pubmed: 30455458
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Nat Commun. 2017 Nov 24;8(1):1776
pubmed: 29176664
Neurosci Biobehav Rev. 2014 Oct;46 Pt 2:187-201
pubmed: 24594195
J Proteomics. 2020 Jan 6;210:103537
pubmed: 31629059
Neurobiol Dis. 2009 Aug;35(2):219-33
pubmed: 19442733
Elife. 2016 Jun 21;5:
pubmed: 27328321
PLoS One. 2014 Mar 25;9(3):e92169
pubmed: 24667344
J Cent Nerv Syst Dis. 2014 Apr 07;6:21-8
pubmed: 24737935
Nat Rev Neurol. 2017 Jan;13(1):37-51
pubmed: 27934853
J Clin Invest. 2015 Aug 3;125(8):2914-23
pubmed: 26237041
Nat Rev Neurosci. 2008 May;9(5):331-43
pubmed: 18382465
Commun Biol. 2019 May 1;2:153
pubmed: 31069263
J Neurosci. 2014 Feb 12;34(7):2754-63
pubmed: 24523563
Nat Rev Neurosci. 2018 Jun;19(6):368-382
pubmed: 29740174
Neurosci Biobehav Rev. 2019 Dec;107:115-135
pubmed: 31108160
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):751-6
pubmed: 26733678
Exp Neurol. 1999 Apr;156(2):345-52
pubmed: 10328941
PLoS One. 2013 Jul 19;8(7):e68851
pubmed: 23894354
PLoS One. 2013 May 22;8(5):e64014
pubmed: 23717525

Auteurs

Alfonso Oyarzabal (A)

Synaptic Metabolism Lab, Neurology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu and CIBERER, 08950 Barcelona, Spain.

Clara Xiol (C)

Genetics Department, Institut Pediàtric de Recerca Hospital Sant Joan de Déu, 08950 Barcelona, Spain.

Alba Aina Castells (AA)

Genetics Department, Institut Pediàtric de Recerca Hospital Sant Joan de Déu, 08950 Barcelona, Spain.

Cristina Grau (C)

Synaptic Metabolism Lab, Neurology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu and CIBERER, 08950 Barcelona, Spain.

Mar O'Callaghan (M)

Neurology Department, Institut Pediàtric de Recerca Hospital Sant Joan de Déu, and CIBERER, 08950 Barcelona, Spain.

Guerau Fernández (G)

Genetics Department, Institut Pediàtric de Recerca Hospital Sant Joan de Déu, 08950 Barcelona, Spain.

Soledad Alcántara (S)

Neural Development Lab, Departament de Patologia i Terapèutica Experimental, Institut de Neurociènces, Universitat de Barcelona, IDIBELL, 08950 Barcelona, Spain.

Mercè Pineda (M)

Neurology Department, Institut Pediàtric de Recerca Hospital Sant Joan de Déu, and CIBERER, 08950 Barcelona, Spain.

Judith Armstrong (J)

Genetics Department, Institut Pediàtric de Recerca Hospital Sant Joan de Déu, 08950 Barcelona, Spain.

Xavier Altafaj (X)

Bellvitge Biomedical Research Institute, Neuropharmacology and Pain Unit, University of Barcelona, 08950 Barcelona, Spain.

Angels García-Cazorla (A)

Synaptic Metabolism Lab, Neurology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu and CIBERER, 08950 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH